FIVE YEARS SURVIVAL OF WOMEN WITH VARIOUS BREAST CANCER STAGES. RETROSPECTIVE RESEARCH
Keywords:
mammary cancer; stages of cancer; special treatment; survival rateAbstract
Introduction: Analysis of sample allows estimating reserves of the clinical control of a cancer, for example - research of five-year survival depending from a stage of the tumor growth motivates development of practice of early diagnostics (of screening).
Aim: To estimate the probability of the five-year survival of patients with MC in sample them from clinic stream of TCB of RSSPMCO&R depending on a stage of tumor growth during 2017-2022 - in the conditions of absence of the developed practice of MC screening.
Material and methods: A casual selection with formatting of the sample from a stream of patients with MC who were treated in period from 01.07.2017 to 31.12.2022; an estimation of their probability of five year survival. Control date (CD) supervision - 01.04.2023
Results: The women who were taken on the dispensary account with diagnosis of MC for the first time and had been treating in clinic of TCB of RSSPMCO&R constituted about three quarters (76,0%) of the stream of patients which was formed by this clinic. The basic fraction of this stream (45,4 %) was constituted by patients with II stage of MС. The fractions of patients with III-IV stages constituted accordingly 21,8%, 14,9% and these were above statistically (p<0,05) than fraction of patients with 0-I stages (9,1%). The fraction of patients without detected stage of MC (8,9%) was statistically identical to fraction of patients with 0-I stages. During first three years after the beginning of special treatment the survival rate at patients of sample was above (p<0,05) than the same rate at the population level (79,5% (CI95%=77,9÷81,0)). Five-year survival of patients in clinical sample constituted 82,1% (CI95%=78,6÷85,6), and this was statistically above (p>0.05) than same coefficient at population level. At stages 0-I, II, III and IV of MC these coefficients of survival were accordingly 93,0, 87,5, 77,7 and 65,5%, and at patients without detected stage of MC - 78,4%.
Conclusion: The five-year survival of patients with 0-I-II-nd stages of MC in clinical sample is statistically equal to survival rate on the population level in socio-economically developed countries of the world. The five-year survival at population level in Tashkent city is significantly limited by a high fraction of patients with III-IV-th stages of MC and fraction of patients without detected stage of MC. This is related with absence of the developed practice of screening in a city.
References
Ahmad A. Breast cancer statistics: Recent trends. //Adv Exp Med Biol. 2019;1 (152):1-7.
Balasubramanian R., Rolph R., Morgan C., Hamed H. (2019). Genetics of breast cancer: management strategies and risk-reducing surgery. // Br.J.Hosp. Med. (Lond). 80 (12): 720-725.
Bray F., Ferlay J., Soerjomataram I. e.a. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries //CA: A Cancer Journal for Clinicians. 68 (6): 394- 424.
Breast cancer: prevention and control // WHO. (https://web.archive.Org/web/20150906121739/http://www.who.-int/cancer/detection/breastcancer/en/indexl .html).
Kirkwood В.R., Sterne J.A.S. Essential medical statistics / 2nd edition, Oxford. - 2003. – 512p.
McGuire A., Brown J.A., Malone C. e.a. 2015. Effects of age on the detection and management of breast cancer. // Cancers. 7 (2): 908-29;
Olopade O.L, Falkson C.I. (2010). Breast Cancer in Women of African Descent. Springer Science & Business Media, p.5.
World Cancer Report. (2008). IARC. Archived from the original (http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr_2008.pdf).
World Cancer Report. (2014). WHO. 2014. pp. Chapter 1.1. ISBN 978-92-832-0429-9.
Кутлумуратов А.Б., Поляков К.И, Вайсбейн И.З, Попов М.С. (2013) О новых тенденциях трехлетней выживаемости онкологических больных на популяционной уровне в Калининградской области// Российский онкологический журнал. – 2013., т.18, №5. – C.42-47. https://rjonco.com/1028-9984/article/view/40038; DOI: https://doi.org/10.17816/onco40038.
Лакин Г.Ф. Биометрия: Учеб. пособие для биол. спец. вузов—4-е изд., перераб. и доп.—М.: Высш. шк., 1990.—352 с.
Мерабишвили В.М. Онкологическая статистика (традиционные методы, новые информационные технологии): Руководство для врачей. Изд-е 2-е, доп-е. Ч I., 2015.- 223с.
Поляков К.И., Кутлумуратов А.Б., Вайсбейн И.З., Попов М.С. Об изменении выживаемости больных со злокачественными новообразованиями молочной железы в Калининградской области.// Здравоохранение Российской Федерации. – 2014, №3. - С.28-34.
Сборник стандартов и клинических протоколов диагностики и лечения злокачественных новообразований / Коллектив составителей, под ред. проф., д.м.н. М.Н. Тилляшайхова. – Ташкент. - 2017. – 254с.
Стрелков Р.Б. Статистические таблицы для экспресс-расчётов стандартной ошибки и доверительных границ при нулевом и стопроцентном значении показателей экспериментальных и клинических данных. – Обнинск, 1982.
Rizaev , J. A. , and A. I. Khazratov . " Cytostructural changes in the oral mucosa in colon cancer." Journal of Biomedicine and Practice 6.5 (2020).
Alshahrani, M. Y., Oghenemaro, E. F., Rizaev, J., Kyada, A., Roopashree, R., Kumar, S., ... & Abosaoda, M. K. (2025). Exploring the modulation of TLR4 and its associated ncRNAs in cancer immunopathogenesis, with an emphasis on the therapeutic implications and mechanisms underlying drug resistance. Human Immunology, 86(1), 111188.
Rizaev JA, Maeda H., Khramova NV Plastic surgery for the defects in the maxillofacial region after surgical resection of benign tumors //Annals of Cancer Research and Therapy. – 2019. – T. 27. – no. 1. – S. 22-23.
